Medizinische Universität Wien
Medizinische Universität Wien
Author: sri_mamah
Bernhard Nocht Institut für Tropenmedizin
Bernhard Nocht Institut für Tropenmedizin
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen
Centro de investigação de Saúde de Manhiça
Centro de investigação de Saúde de Manhiça
Centre de Recherches Médicales de Lambaréné
Centre de Recherches Médicales de Lambaréné
Dr Markus Zeitlinger
Medical Universitu Vienna (MUW)
Pharmacokinetics
Dr Valérie Briand
Bordeaux Population Health Research Center / Université de Bordeaux
Malaria in Pregnancy
Chair of DSMB
Mr Sergi Sanz
ISGlobal, Bioestatistician
Dr Mireia Piqueras
ISGlobal, Project Manager
WP1 leader
Prof. Clara Menéndez
ISGlobal, Project Coordinator
Dr Raquel González
ISGlobal, Technical Coordinator
WP6 leader
Dr Heimo Lagler
MUW, Principal Investigator
Dr Francisco Saúte
FM, Investigator
WP2 leader
Dr Esperança Sevene
FM, Investigator
Dr Tacilta Nhampossa
FM, Principal Investigator
Dr Meral Esen
EKUT, Principal Investigator
WP5 leader
Dr Ghyslain Mombo-Ngoma
CERMEL, Principal Investigator
WP4 leader
1
1. Menendez C, Ferenchick E, Roman E, Bardaji A and Mangiaterra V., Malaria in pregnancy: challenges for control and the need for urgent action. The Lancet Global health. 2015; 3:e433-4.
2
2. WHO. Malaria and HIV interactions and their implications for public health policy WHO. 2005; ISBN 92 4 1593350.
Dr Fernando José García Lopez.
President of the Committee for Ethical Research (CEI) of the Institute of Health Carlos III (ISCIII).
Doctor of medicine and surgery. Master in Bioethics and Law. Head of Section of the area of
Applied Epidemiology at the National Center of Epidemiology. III.
Dr Kassoum Kayentao
Malaria Research and Training Center (MRTC) / University of Bamako
Malaria in Pregnancy
Institut de Salut Global de Barcelona
Institut de Salut Global de Barcelona
Dr Johannes Mischlinger
BNITM, Investigator
Prof. Michael Ramharter
BNITM, Principal Investigator
WP3 leader
The Project
Malaria infection during pregnancy is an important driver of maternal and neonatal health especially among HIV-infected women. In Africa, at least one million pregnancies are co-infected with malaria and HIV annually. The interaction between the two infections is particularly deleterious in pregnancy, leading to increased risk of malaria and HIV viral load, which may increase the frequency of mother to child transmission of HIV (MTCT-HIV). Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is recommended for malaria prevention in HIV-uninfected women but it is contraindicated in those HIV-infected on cotrimoxazole prophylaxis (CTXp) due to potential adverse effects.
A recent trial showed that an effective antimalarial added to CTXp and long-lasting insecticide treated nets (LLITNs) in HIV-infected pregnant women improves malaria prevention and maternal health. However, the antimalarial used –mefloquine- was not well tolerated and it was associated with an increase in HIV viral load at delivery and a two-fold increased risk of MTCT-HIV. These findings highlight the need to find alternative drugs with better tolerability and safety profile to prevent malaria in this vulnerable group and to further study the pharmacological interactions between antimalarials and antiretrovirals (ARVs).
Overview of workplan
The project will include six work packages (WPs). Two of them (WP1 and WP6) relate to the Project Management and Communication, Advocacy and Exploitation activities, whereas WP2, and 3 comprise the main research tasks, and 4 and 5 will address Capacity Building and Networking actions. ISGlobal, as overall Project Coordinator leads the aforementioned WPs 1 and 6.
Malaria in Pregnancy: Intermittent Preventive Treatment
A cost-effective intervention for preventing maternal and newborn mortality
Plasmodium falciparum malaria during pregnancy can result in negative outcomes in maternal and child health. In malaria stable transmission areas in Africa, approximately 25 million pregnancies are exposed every year to the infection. An estimated 10,000 of these women and 200,000 of their infants die as a result of malaria infection during pregnancy, and severe malarial anaemia contributes to more than half of these deaths.
ZIKA-Preg
Recently, the causal relationship between prenatal Zika virus infection and microcephaly and other serious brain anomalies has been confirmed. This outbreak represents a global health emergency of devastating consequences for maternal and foetal health. Currently, Zika virus cases have been documented in a total of 75 countries and territories.
Work Packages
Overview of workplan
The project will include six work packages (WPs). Two of them (WP1 and WP6) relate to the Project Management and Communication, Advocacy and Exploitation activities, whereas WP2, and 3 comprise the main research tasks, and 4 and 5 will address Capacity Building and Networking actions. ISGlobal, as overall Project Coordinator leads the aforementioned WPs 1 and 6.
Access to Preventive Malaria Treatment for Pregnant Women Has Increased Five-Fold in the Last Five Years
On December 13, the WHO released the World Malaria Report 2016, an annual report that tracks the progress and trends in malaria control and elimination at a global, regional and national level. Using data from 91 countries with malaria transmission and the help of numerous partners, the report indicates that children and pregnant women in sub-Saharan Africa have greater access to effective tools against malaria. “The news are very positive” says Clara Menéndez, director of the Maternal, Child and Reproductive Health Initiative at ISGlobal, “first, because it affects two of the most vulnerable populations to malaria in the world, African children and pregnant women, and secondly, because it reflects that a collaborative effort between ministries of health and many partners is possible and may achieve positive results.”